Teva Releases Q1 2025 Aide Memoire
March 27, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
March 27, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™…
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
December 05, 2024 18:00 ET | Source: Teva Pharmaceutical Industries Ltd Teva…
Teva to Present at the Jefferies London Healthcare Conference
November 08, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…